Abstract
1 previously untreated patient with plasma-cell leukaemia and 8 patients with myeloma (4 previously untreated) were treated with high-dose melphalan 100-140 mg/m2 iv. All responded to treatment. 3 of the 5 previously untreated patients achieved biochemical and bone-marrow complete remissions.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Age Factors
-
Bence Jones Protein / urine
-
Bone Marrow Transplantation
-
Female
-
Humans
-
Injections, Intravenous
-
Leukemia, Plasma Cell / drug therapy*
-
Leukemia, Plasma Cell / therapy
-
Male
-
Melphalan / administration & dosage*
-
Melphalan / adverse effects
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / therapy
-
Neutropenia / chemically induced
-
Pain Management
-
Transplantation, Autologous
Substances
-
Bence Jones Protein
-
Melphalan